Rallybio (RLYB)
(Delayed Data from NSDQ)
$1.30 USD
-0.04 (-2.99%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.31 +0.01 (0.77%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RLYB 1.30 -0.04(-2.99%)
Will RLYB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RLYB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLYB
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
RLYB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect?
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
Other News for RLYB
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
Rallybio (RLYB) Receives a Buy from TD Cowen
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
Rallybio reports results from epidemiological analysis evaluating FNAIT risk
Buy Rating Affirmed for Rallybio as RLYB212 Shows Blockbuster Potential in Underserved FNAIT Market